{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-001328","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.166379+00:00","generated_at":"2026-06-10T08:46:31.241016+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arcturus extends CF Foundation deal; total funding up to ~$25M for ARCT-032 CF program","bullets":["CF Foundation increases financial commitment to ~$25M to advance ARCT-032, an mRNA therapeutic for cystic fibrosis.","Arcturus to provide $15M in matching funds; royalty rates and caps modified with option to reduce via one-time payment.","Agreement extends prior program initiated in 2017; Phase 1b study in adults with CF planned imminently.","ARCT-032 is mutation-agnostic and aims to express functional CFTR protein in the lung, addressing root cause of CF."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-001328","json":"https://secwatch.observer/filing/0001193805-23-001328.json","markdown":"https://secwatch.observer/filing/0001193805-23-001328.md","text":"https://secwatch.observer/filing/0001193805-23-001328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001328/0001193805-23-001328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001328/e618944_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:46:31.241016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f425bcb4f3d741e8c7f586c272f2673c3aaddfa","claim":"Arcturus Therapeutics Holdings Inc. amended the \"Amendment\" with Cystic Fibrosis Foundation valued at up to $9 million (effective 2023-09-25).","evidence_excerpt":"On September 25, 2023, Arcturus Therapeutics, Inc. (\" Arcturus \"), a subsidiary of Arcturus Therapeutics Holdings Inc. (the \" Company \"), entered into an amendment (the \" Amendment \") to its Development Program Letter Agreement of May 16, 2017","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001328/0001193805-23-001328-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Cystic Fibrosis Foundation"},{"label":"Value","value":"up to $9 million"},{"label":"Effective","value":"2023-09-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}